Maxi-Analgesic Dose Response Study

The combination of 500 mg acetaminophen and 150 mg ibuprofen has been shown to improve
analgesia compared with the individual components, when given as 2 tablets (i.e., total of
1,000/300 mg) 4 times a day for dental pain.

The analgesic relief from 2 tablets of the combination was around 6 hours, and so consistent
with 4 times a day dosing.

The combination tablets are scored to allow for lower doses and can be given as 2 tablets
(total of 1,000/300 mg), 1 tablet (500/150 mg) or ½ tablet (250/75 mg) in multiple doses.

However different dose response combinations need to be investigated to confirm the dose
response curve of the combination and to compare the relative efficacy with acetaminophen
and different doses of ibuprofen (lower and higher dose).

The study hypothesis is the analgesic response to three different combination doses, the
three single component doses 500mg acetaminophen and 150mg and 300mg ibuprofen, and placebo
administered four times daily over 24 hours for post-operative dental pain will form a
representative dose response curve.

The study design is multi-centre, prospective, placebo-controlled, randomized, double-blind,
factorial parallel group.

Participants will be stratified for baseline pain at inclusion (moderate or severe pain
based a 4 point pain intensity rating scale).

Recruitment will continue until there are at least 350 participants in the ITT population.

Efficacy: The primary efficacy objective is to compare the time-adjusted SPIDs (Summed Pain
Intensity Differences) of the VAS pain intensity scores up to 24 hours after the first dose
of study medication among the 7 treatment groups to determine the form of the dose-response
relationship.

Secondary efficacy objectives are:

- To compare the maximum VAS pain scores for the 24-hour period after the first dose of
study medication among the seven treatment groups to determine the form of the dose
response relationship.

- To compare the response rates (response rate to be defined as the percentage of
participants who achieve at least 50% reduction in baseline pain within 6 hours i.e.
the first dose period) among the seven treatment groups to determine the form of the
dose response relationship.

- To determine and compare the time to peak reduction in VAS pain intensity scores
following the first dose of study medication among the seven treatment groups to
determine the form of the dose response relationship.

- To compare time to perceptible and meaningful pain relief among the seven treatment
groups using the two stopwatch method.

- To compare the time to requirement for rescue medication among the seven treatment
groups.

- To compare the amount of rescue medication used (defined as the number of tablets)
among the seven treatment groups over the 24-hour treatment period.

- To compare the percentage of participants requiring rescue medication among the seven
treatment groups.

- To compare the categorical global pain rating among the seven treatment groups.

Safety:

To compare adverse event rates (divided into serious and non-serious adverse events).
Adverse events will be assessed for the 24- hour study period and up to 30 days after the
final dose of study medication among the seven treatment groups.

The standard symptoms expected in subjects who have recently undergone third molar
extraction will not be recorded as AEs in this study, unless they are of greater severity
and/or intensity than would be expected. The events considered to be standard for the
purposes of this study are:

- Oral pain.

- Facial swelling.

- Oral bleeding.

- Bruising to face, neck, and/or jaw.

- Decreased range of motion of the jaw.

- Dry socket.

The Investigators will use their clinical judgement in determining whether these symptoms
are of greater severity and/or intensity than would be expected.

Planned hospital admissions and/or surgical operations for an illness or disease which
existed before the drug was given or the participant was randomized in a clinical study will
not be considered adverse events The incidence of known specific NSAID and acetaminophen
side effects (e.g. GI ulceration, Indigestion/stomach pain, post-operative bleeding,
thromboembolic events and evidence of clinical hepatitis) during the 24-hour study period
and up to 30 days after the last dose will be compared among the seven treatments.

Inclusion Criteria:

1. Provide written informed consent before initiation of any study-related procedures.

2. Males and females aged at least 16 years and not more than 40 years old on the day of
consent.

3. Undergoing oral surgery for the extraction of 2 impacted 3rd molar teeth, one of
which must be mandibular and require bone removal.

4. Experiencing moderate to severe post-operative pain, as defined by a 4 point
categorical pain intensity rating scale with 0 = no pain; 1 = mild pain; 2 = moderate
pain and 3 = severe pain(at rest) within 6 hours after completion of surgery.

5. Baseline VAS pain intensity score of > 50mm on a 100mm VAS scale with 0 = no pain and
100 = worst pain imaginable.

Exclusion Criteria:

Study contra-indications:

1. Has taken any NSAID or acetaminophen within 12 hours prior to the start of surgery
other than aspirin ≤ 150mg/day.

2. Subjects who have received any anesthetics from midnight the night prior to surgery,
except for lidocaine with epinephrine, nitrous oxide, diazepam (Valium®),
methohexital (Brevital®).

3. Known to be pregnant or possibly pregnant.

4. Women of childbearing potential who are unwilling to take adequate contraceptive
precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier
method, or abstinence (should the subject become sexually active, she must agree to
use a double-barrier method of contraception). A woman of childbearing potential is
defined as any female who is less than 2 years post-menopausal or has not undergone a
partial or total hysterectomy or surgical sterilization, e.g., bilateral tubal
ligation, bilateral oophorectomy.

5. Suffering from a neurological disorder relating to pain perception or any acute or
chronic condition that, in the opinion of the investigator, makes the subject
unsuitable from an efficacy or safety perspective.

6. In the opinion of the investigator, unable to understand the visual analogue pain
score or comply with the protocol requirements.

7. Currently or in last 30 days, has been in a clinical trial involving another study
drug.

8. Currently treated with an ACE inhibitor, warfarin, steroid (other than nasal steroids
or topical steroids with the approval of the investigator), cyclosporin, tacrolimus
or methotrexate, or any other medication felt by the investigator to interfere with
safety or efficacy evaluations.

9. Participant weight < 50kg.Suffering from any other diseases or condition which, in
the opinion of the investigator, means that it would not be in the participant's best
interests to participate in this study.

NSAID and/or acetaminophen contra-indications:

10. Hypersensitivity to aspirin or other NSAID.

11. Hypersensitivity to acetaminophen.

12. Severe known hemopoietic, renal or hepatic disease, or immunosuppressed.

13. History of gastric ulceration or other GI disorders that, in the opinion of the
investigator make the subject unsuitable (e.g., frequent treatment of GERD,
inflammatory bowel disease, etc.).

14. History of severe asthma defined as asthma requiring frequent or ongoing treatment to
control symptoms. Exercise-induced asthma or mild asthma not requiring ongoing
treatment may not be exclusionary at the discretion of the investigator.